BioNTech (NASDAQ:BNTX) Shares Gap Down – Time to Sell?

BioNTech SE (NASDAQ:BNTX) shares gapped down before the market opened on Friday . The stock had previously closed at $103.56, but opened at $99.89. BioNTech shares last traded at $97.91, with a volume of 505,019 shares.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. TD Cowen reduced their price target on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research report on Tuesday, November 5th. UBS Group lifted their price objective on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. Canaccord Genuity Group reissued a “buy” rating and issued a $171.00 target price on shares of BioNTech in a report on Thursday. HSBC lifted their price target on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Finally, Bank of America increased their price objective on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Four analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and an average price target of $137.54.

BioNTech Stock Performance

The stock’s 50-day moving average is $113.54 and its 200-day moving average is $97.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The stock has a market cap of $23.91 billion, a price-to-earnings ratio of -47.49 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business’s revenue was up 38.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.73 earnings per share. Analysts anticipate that BioNTech SE will post -3.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Covestor Ltd grew its holdings in BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares during the period. GAMMA Investing LLC grew its stake in shares of BioNTech by 86.9% during the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after buying an additional 238 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after buying an additional 252 shares during the last quarter. Planning Capital Management Corp increased its holdings in shares of BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after buying an additional 450 shares during the last quarter. Finally, Blue Trust Inc. raised its position in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after buying an additional 388 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.